Loading the company…
Loading the company…
No clearances or recalls under the mapped product codes.
All companies · Product and company coverage
In 2025, Omnilife Science reported engagement with 15 surgeons and other clinicians in the states MedaRep covers, worth $36K in consulting, speaking, meals and travel for its device products, the most in Texas ($15K to 3). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($15K, 3 engaged), Wisconsin ($9,075, 1 engaged), North Carolina ($5,181, 1 engaged), California ($2,643, 2 engaged), Colorado ($1,696, 1 engaged).
In the last ten years FDA made 4 decisions for Omnilife Science (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 0 procedure families, the most in 2017 (3). The latest was on 2021-04-02.
| Apex Revision Knee System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Omnilife Science.